QuickOEM EN · Case Studies

Inside the Dermocosmetics Wave: Claim, Evidence, Pharmacy Shelf

Dermocosmetics is no longer a niche shelf in the European pharmacy channel. The brands winning it have built a closed loop: a claim, the evidence that supports it, and a manufacturing run size that the evidence can actually afford.

📅 Updated 2026-09-27 · 🏷️ Case Study · ⏱️ 9 min

Key Facts · 2026-09-27

  • Cosmetic claims in the EU must substantiate the benefit with evidence, and Regulation 655/2013 sets the common criteria that authorities apply when checking them.
  • An evidenced active needs concentration, formulation context and a study, which is why dermocosmetic MOQs sit at 1,000-3,000 units for serums and 2,000-4,000 for anti-ageing creams.
  • Anti-ageing and active-led creams are quoted at 2,000-4,000 units per SKU, well above the 500-1,000 unit band for cleansers and toners.
  • Stability testing consumes part of every batch, so the quantity needed for a 3-month real-time study plus a preservative challenge is drawn from the run itself, not added later.
  • Pharmacy buyers in Germany and France expect dermatologically tested, fragrance-free or pH 5.5 packaging as a listing prerequisite rather than a differentiator.
  • Regulation 655/2013 governs the common criteria for claims, and each claim on an own-label dermocosmetic must be defensible to a pharmacist reading the Product Information File.
2,000-4k
Units per anti-ageing SKU
655
Regulation on common criteria
3
Evidence links in the chain
6-12
Months for a full custom line

What Dermocosmetics Actually Means on a Pharmacy Shelf

Dermocosmetics sits between cosmetology and dermatology. On a European pharmacy shelf it describes products positioned for compromised or reactive skin, where the brand talks about a barrier function, a pH level or a specific active rather than about luxury texture. In Germany and France, pharmacists are the ones who end the conversation, and they are sceptical by default.

That scepticism is the reason this category is hard to fake. A dermocosmetic brand cannot buy its way onto the shelf with packaging and distribution alone, because the person recommending it to the customer has probably already read the formula.

In this channel the pharmacist is the media buyer. If the file does not hold up, there is no campaign.

The Claim to Evidence Loop

A claim is the public sentence. The evidence is everything behind it: the concentration used, the study that tested it, the excipient context that made it work, and the stability data proving the concentration survives to the end of the shelf life. Regulation 655/2013 introduced common criteria for exactly this chain, and national authorities in Germany and France apply them in practice.

The loop fails in one of only two places. Either the brand published a claim the evidence does not support, or the evidence exists but was never written into the Product Information File in a way a regulator could use.

How the Evidence Chain Dictates the Order Quantity

This is the part most brands discover late. An evidenced active does not behave like a stock formula, because the study was run on a specific emulsion at a specific concentration. Change the emulsifier system to save cost and the study no longer describes the product in the bottle.

Stability and preservative challenge testing are therefore part of the minimum batch, not a charge added afterwards. That is why dermocosmetic runs are larger than the equivalent white-label product and why they take longer to qualify.

  1. Fix the active concentration and the study first, before anyone talks about volume.
  2. Scale the base to match the study, then lock the formula so the evidence still applies to the finished product.
  3. Reserve part of the first production batch for stability and challenge testing.
  4. Run at least three months of real-time data before committing the dating and the marketing copy.
  5. Only then set the MOQ, which for serums lands around 1,000-3,000 units and for anti-ageing creams around 2,000-4,000.

Rebuilding a Range Around Actives

A pharmacy brand rebuilding its assortment usually cuts the middle first. Gentle cleansers and basic moisturisers get either retired or moved into a cheaper own-label line, and the margin moves into two or three serum or cream SKUs where the story is strong enough to survive pharmacist scrutiny.

The move is deliberate. Fewer SKUs, each carrying more evidence, is a defensible range. A wide shelf of unverified claims is not.

What Suppliers Should Expect From the Loop

For a manufacturer, the practical implication is that dermocosmetic projects are longer and more technical than a cosmetic one, and should be priced that way. Six to twelve months is normal for a fully custom active-led line, and much of that is testing rather than filling.

The European pharmacy channel also rewards restraint in other ways. Dermatologically tested, fragrance-free and a stated pH are treated as gate conditions; a brand that overstates an active will lose the listing long before a regulator asks.

Volume follows evidence. If you lock the MOQ before the study, you will be reformulating.

Frequently Asked Questions

What makes a product dermocosmetic rather than ordinary skincare?
Dermocosmetics target compromised or reactive skin and are positioned around barrier function, pH or a specific active concentration. In European pharmacy channels they are sold with a claim a pharmacist will repeat, so the evidence behind that claim matters as much as the formula.
What rules govern cosmetic claims in the EU?
Regulation 655/2013 sets the common criteria authorities use to judge whether a cosmetic claim is substantiated. The criteria cover evidence sufficiency, consumer perception, responsible-person accountability and fairness. National regulators in Germany and France apply them in practice during market surveillance checks.
Why does an evidenced active increase the minimum order quantity?
The study that supports the claim was run on a specific concentration in a specific base, so changing the formula invalidates it. Stability and preservative challenge testing also draw samples from the production batch, which means the qualifying quantity is part of the minimum run rather than an extra.
How many units do dermocosmetic serums and creams need?
Serums typically start at 1,000-3,000 units per SKU and anti-ageing or active-led creams at 2,000-4,000 units. Cleansers and toners sit much lower at 500-1,000 units. Because stability and challenge testing draw samples from the qualifying batch, an evidence-led line commits to a higher volume up front.
How long does an active-led private label line take to qualify?
A fully custom active-led line usually takes 6-12 months, and stability testing rather than production defines the calendar. A base-derived semi-custom line runs 3-5 months because of sampling. A white-label stock formula can still ship in 2-4 weeks when no new evidence work is required.
What do pharmacy buyers in Germany and France check first?
They check claim restraint, ingredient legibility on the INCI list and dermatological testing status first. Packaging claims such as dermatologically tested, fragrance-free or a stated pH are treated as prerequisites for listing rather than as differentiators in this channel. Ambitious claims lose the listing.

Related Resources

From Reseller to Own Label: What a Regional Distributor Had to Give Up

A regional distributor lost resale margin to online retail, so it launched its own label. The real costs were inventory, compliance and channel conflict.

European Drugstore Own Label: The Margin Math Behind the Rise

Own-label share keeps rising across European drugstore shelves. The margin structure, localisation rules and compliance spend that come first.

Halal Skincare Export: How Gulf and Indonesian Buyers Screen a Factory

Halal, vegan and cruelty-free are three parallel tracks into Gulf and Indonesian shelves. Here is what each buyer checks first, and why halal raises MOQ.

How a Three-Person Team Launched 24 SKUs on a 500-Unit MOQ

A three-person team built a 24-SKU skincare range on a 500-unit MOQ. Here is the budget and trade-offs behind a low-MOQ private-label launch in 2026.

Build an evidenced active line

Send us the claims you intend to make and your target pharmacy market. We will confirm which actives carry defensible evidence, the testing timeline and the batch size that supports it.

Start your match